University of Pennsylvania

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1740-11-14

Employees: 5K

Market Cap: -

Website: http://www.upenn.edu

Clinical Trials

Zaleplon in HIV Patients With Depression

Phase 2

Completed

Conditions: HIV/AIDS
Clinical Depression

Interventions: Drug: Zaleplon

First Posted Date: 2018-04-05

Last Posted Date: 2018-10-16

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 20

Registration Number: NCT03489304

Locations: 🇺🇸
Mood & Anxiety Disorders Research and Treatment Program, Philadelphia, Pennsylvania, United States

Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)

Phase 2

Completed

Conditions: Aortic Valve Stenosis

Interventions: Drug: Potassium Nitrate
Drug: Potassium Chloride

First Posted Date: 2018-03-29

Last Posted Date: 2020-06-17

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 5

Registration Number: NCT03483051

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

Phase 2

Recruiting

Conditions: Churg-Strauss Syndrome (CSS)
Polyarteritis Nodosa
Giant Cell Arteritis
Granulomatosis With Polyangiitis
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Microscopic Polyangiitis
Takayasu Arteritis

Interventions: Other: Placebo Comparator
Drug: Naltrexone Hydrochloride

First Posted Date: 2018-03-29

Last Posted Date: 2024-05-21

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 36

Registration Number: NCT03482479

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States

and more 4 locations

Low Dose Fat-Induced Insulin Resistance

Early Phase 1

Recruiting

Conditions: Diabetes Mellitus, Type 2
Insulin Resistance
Insulin Sensitivity

Interventions: Drug: Intralipid, 20% Intravenous Emulsion

First Posted Date: 2018-03-27

Last Posted Date: 2024-01-31

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 12

Registration Number: NCT03479671

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Acute Effects of E-Cigarette Aerosol Inhalation

Early Phase 1

Completed

Conditions: Endothelial Dysfunction
Biochemical Markers

Interventions: Drug: Electronic Cigarette Aerosol

First Posted Date: 2018-03-27

Last Posted Date: 2024-05-08

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 31

Registration Number: NCT03479203

Locations: 🇺🇸
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States

Serial SMS Reminders and an Opt-out Mailed FIT Kits to Improve Colorectal Screening Participation: A Single Center RCT

Not Applicable

Completed

Conditions: Colon Cancer
Bowel Cancer

Interventions: Behavioral: Serial text messages and mailed FIT kit

First Posted Date: 2018-03-27

Last Posted Date: 2019-07-22

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 440

Registration Number: NCT03479645

Locations: 🇺🇸
Family Practice and Councelling Network, Philadelphia, Pennsylvania, United States

Perfusion Enhancement With Respiratory Impedance in Stroke (PERI-Stroke)

Not Applicable

Completed

Conditions: Stroke

Interventions: Other: Respiratory Impedance (RI)

First Posted Date: 2018-03-26

Last Posted Date: 2024-02-20

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 20

Registration Number: NCT03476954

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: High Grade Serous Carcinoma

Interventions: Drug: Olaparib Pill
Drug: AZD6738

First Posted Date: 2018-03-12

Last Posted Date: 2024-10-03

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 86

Registration Number: NCT03462342

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Prospective Evaluation of Facial Cosmetic Procedures

Phase 4

Completed

Conditions: Cosmetic Techniques

Interventions: Drug: Restylane-L®
Drug: Restylane-L® Lyft
Drug: Restylane Silk®

First Posted Date: 2018-03-09

Last Posted Date: 2024-09-27

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 101

Registration Number: NCT03460158

Locations: 🇺🇸
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States

Thermal Camera Detection of Ventriculoperitoneal Shunt Flow

Completed

Conditions: Hydrocephalus

First Posted Date: 2018-03-02

Last Posted Date: 2020-05-11

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 2

Registration Number: NCT03451669

Locations: 🇺🇸
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy